title: Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy.
abstract: OBJECTIVE
  The relationship between MDR1 single nucleotide polymorphisms (SNP) and the pharmacokinetic or pharmacodynamic responses to protease inhibitors has been recently challenged.
  
  
  OBJECTIVE
  The objective of the present study was to determine whether MDR1 genetic polymorphisms in exons 21 and 26 (G2677T/A and C3435T) are in association with indinavir (IDV) plasma concentrations and/or therapeutic response to highly active antiretroviral therapy (HAART) in HIV-infected patients treated with unboosted IDV containing regimens.
  
  
  METHODS
  MDR1 genotyping was performed in a population of 139 HIV-1-positive patients followed during 72 weeks, as part of the previous study called ANRS 081 'Trianon'. The primary study was a randomized trial comparing over 72 weeks the efficacy of two antiretroviral drug combinations in a population of adult HIV-1-infected patients: group 1, [lamivudine (3TC) - stavudine (d4T) - IDV (800 mg three times daily)] and group 2, [Nevirapine (NVP) - d4T - IDV (1000 mg three times daily)].
  
  
  RESULTS
  MDR1 SNPs analyzed separately or combined into haplotypes did not show any significant association with IDV pharmacokinetics nor response to HAART. Mean modelled IDV peak and trough concentrations, as well as clearance modelled from pharmacokinetic model, after 8 weeks of therapy were not significantly different between patients carrying the wild-type haplotype GG-CC (at position 2677 and 3435 respectively) and others.
  
  
  CONCLUSIONS
  Our results do not support an association between MDR1 genetic polymorphisms and modelled IDV clearance or clinical response to HAART.
authors.affiliation: Pharmacology Department, Saint Antoine hospital, Pierre et Marie Curie University, Paris-VI, Assistance Publique-Hôpitaux de Paris, 37 rue de Chaligny 75012 Paris, France. celine.verstuyft@chusa.jussieu.fr
authors.forename: Céline
authors.initials: C
authors.lastname: Verstuyft
authors.forename: Fabienne
authors.initials: F
authors.lastname: Marcellin
authors.forename: Laurence
authors.initials: L
authors.lastname: Morand-Joubert
authors.forename: Odile
authors.initials: O
authors.lastname: Launay
authors.forename: Karl
authors.initials: K
authors.lastname: Brendel
authors.forename: France
authors.initials: F
authors.lastname: Mentré
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
authors.forename: Laurence
authors.initials: L
authors.lastname: Gérard
authors.forename: Laurent
authors.initials: L
authors.lastname: Becquemont
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Aboulker
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D005787:Gene Frequency; D019450:Genes, MDR / Q000235:genetics*; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics*; D006801:Humans; D019469:Indinavir / Q000493:pharmacokinetics*; D008297:Male; D011110:Polymorphism, Genetic / Q000235:genetics*
chemical_list: D017320:HIV Protease Inhibitors; D019469:Indinavir